Supernus Pharmaceuticals (SUPN) Competitors $32.48 -0.01 (-0.03%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SUPN vs. CORT, JAZZ, PRGO, PCRX, OMER, NKTR, ASMB, CPIX, LLY, and JNJShould you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Omeros (OMER), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry. Supernus Pharmaceuticals vs. Corcept Therapeutics Jazz Pharmaceuticals Perrigo Pacira BioSciences Omeros Nektar Therapeutics Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson Supernus Pharmaceuticals (NASDAQ:SUPN) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk. Does the MarketBeat Community prefer SUPN or CORT? Corcept Therapeutics received 65 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. However, 73.10% of users gave Supernus Pharmaceuticals an outperform vote while only 71.37% of users gave Corcept Therapeutics an outperform vote. CompanyUnderperformOutperformSupernus PharmaceuticalsOutperform Votes48173.10% Underperform Votes17726.90% Corcept TherapeuticsOutperform Votes54671.37% Underperform Votes21928.63% Do insiders & institutionals believe in SUPN or CORT? 93.6% of Corcept Therapeutics shares are held by institutional investors. 9.3% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 20.5% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor SUPN or CORT? In the previous week, Corcept Therapeutics had 2 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 13 mentions for Corcept Therapeutics and 11 mentions for Supernus Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 1.43 beat Supernus Pharmaceuticals' score of 0.87 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Corcept Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer SUPN or CORT? Supernus Pharmaceuticals currently has a consensus price target of $36.00, indicating a potential upside of 10.84%. Corcept Therapeutics has a consensus price target of $143.25, indicating a potential upside of 99.29%. Given Corcept Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Corcept Therapeutics is more favorable than Supernus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Supernus Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, SUPN or CORT? Corcept Therapeutics has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSupernus Pharmaceuticals$661.82M2.74$1.32M$1.3224.61Corcept Therapeutics$675.04M11.23$106.14M$1.2457.97 Which has more volatility & risk, SUPN or CORT? Supernus Pharmaceuticals has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Is SUPN or CORT more profitable? Corcept Therapeutics has a net margin of 22.35% compared to Supernus Pharmaceuticals' net margin of 9.16%. Corcept Therapeutics' return on equity of 24.54% beat Supernus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Supernus Pharmaceuticals9.16% 7.79% 5.67% Corcept Therapeutics 22.35%24.54%20.24% SummaryCorcept Therapeutics beats Supernus Pharmaceuticals on 15 of the 18 factors compared between the two stocks. Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SUPN vs. The Competition Export to ExcelMetricSupernus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.81B$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio30.367.4422.4818.48Price / Sales2.74242.70395.10103.59Price / Cash21.8365.8538.1834.62Price / Book1.936.516.774.25Net Income$1.32M$143.21M$3.22B$248.23M7 Day Performance3.60%1.98%1.50%0.89%1 Month Performance2.53%6.89%4.01%3.53%1 Year Performance7.98%-2.52%16.16%5.08% Supernus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SUPNSupernus Pharmaceuticals3.143 of 5 stars$32.480.0%$36.00+10.8%+7.9%$1.81B$661.82M30.36580Upcoming EarningsCORTCorcept Therapeutics4.8245 of 5 stars$62.90+1.1%$143.25+127.7%+208.2%$6.64B$675.04M49.92300Upcoming EarningsShort Interest ↓Positive NewsJAZZJazz Pharmaceuticals4.838 of 5 stars$100.34-2.4%$187.71+87.1%+5.6%$6.09B$4.07B14.133,200Upcoming EarningsAnalyst RevisionPositive NewsPRGOPerrigo4.862 of 5 stars$24.41-3.6%$33.00+35.2%-21.2%$3.33B$4.37B-20.868,900Upcoming EarningsDividend AnnouncementShort Interest ↑Positive NewsPCRXPacira BioSciences1.9299 of 5 stars$25.90+5.1%$26.67+3.0%+2.5%$1.20B$700.97M-12.76720Upcoming EarningsPositive NewsGap UpOMEROmeros3.8333 of 5 stars$6.70-1.2%$22.50+235.8%+133.3%$389.03MN/A-2.90210NKTRNektar Therapeutics4.0876 of 5 stars$0.63-1.6%$4.50+619.0%-45.5%$116.48M$98.43M-0.75220Upcoming EarningsPositive NewsASMBAssembly Biosciences3.8105 of 5 stars$9.94-0.9%$33.00+232.0%-8.7%$74.58M$28.52M-1.48100Upcoming EarningsNews CoveragePositive NewsCPIXCumberland Pharmaceuticals0.8711 of 5 stars$4.49-5.7%N/A+201.9%$62.72M$37.87M-5.8380Upcoming EarningsShort Interest ↓News CoveragePositive NewsLLYEli Lilly and Company4.92 of 5 stars$818.18-2.6%$1,012.00+23.7%+15.1%$775.77B$45.04B69.8739,000Analyst DowngradeJNJJohnson & Johnson4.3024 of 5 stars$157.00-0.3%$171.82+9.4%+8.1%$378.35B$88.82B23.61152,700 Related Companies and Tools Related Companies CORT Alternatives JAZZ Alternatives PRGO Alternatives PCRX Alternatives OMER Alternatives NKTR Alternatives ASMB Alternatives CPIX Alternatives LLY Alternatives JNJ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SUPN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SUPN Stock Free SUPN Stock Alerts